PhenomeX to Participate in Antibody Engineering & Therapeutics Europe 2023 PR Newswire EMERYVILLE, Calif., June 5, 2023 Company to feature its recently launched Beacon Select™ technology for...
PhenomeX to Participate in American Association of Cancer Research Annual Meeting 2023 PR Newswire EMERYVILLE, Calif., April 7, 2023 EMERYVILLE, Calif., April 7, 2023 /PRNewswire/ -- PhenomeX...
Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company PR Newswire EMERYVILLE, Calif., March 21, 2023 PhenomeX to begin trading under symbol...
Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire EMERYVILLE, Calif., Feb. 23, 2023 EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc...
Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 PR Newswire EMERYVILLE, Calif., Feb. 13, 2023 EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/...
Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results PR Newswire EMERYVILLE, Calif., Jan. 9, 2023 EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq:...
Berkeley Lights Launches Beacon Select™, A New Optofluidic System For Cell Line Development PR Newswire EMERYVILLE, Calif., Jan. 9, 2023 New, two-chip, single-cell optofluidic system ideal for...
Berkeley Lights to Participate in the 41st Annual J.P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 3, 2023 EMERYVILLE, Calif., Jan. 3, 2023 /PRNewswire/ -- Berkeley Lights...
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company PR Newswire EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 Complementary Technologies, Customer...
Berkeley Lights to Showcase its New Beacon® System Workflow to Access Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies at 2022 Antibody Engineering &...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales